Cara Mathews, MD, Talks Dostarlimab for Advance Recurrent Endometrial Cancers


Cara Mathews, MD, spoke with CancerNetwork® about research examining dostarlimab vs doxorubicin for patients with mismatch repair–deficient endometrial cancers.

CancerNetwork® spoke with Cara Mathews, MD, gynecologic oncology specialist at the Women and Infants Hospital of Rhode Island, about cohort results from the GARNET (NCT02715284) and ZopteC (NCT01767155) trials that were presented at The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer examining dostarlimab (Jemperli) compared with doxorubicin in patients with advance recurrent endometrial cancers.


The project that we presented at this meeting is looking at patients who are mismatch repair deficient. Typically, [they have tumors that are] microsatellite unstable and are treated with single-agent dostarlimab, PD-L1 inhibition, compared with patients from the zoptEC trial [NCT01767155], who were treated and matched with a standard doxorubicin arm. We had patient-level data and were able to compare in 2 clinical trial settings where we had very good data, rather than the clinical real-world setting, [to see] what the outcomes were. This is a novel trial method and it’s important because for dostarlimab, the outcomes have been so promising that it would be hard to do a head-to-head comparison for this treatment vs standard chemotherapy. Some would even argue that it might be unethical at this point, so we can use these data from these 2 populations and compare PD-L1 inhibitor vs standard chemotherapy. The results were exciting, and it showed that, not surprisingly, dostarlimab performed very well. Progression-free survival between the 2 arms showed a clear benefit towards dostarlimab, 12 months vs 5 months. In overall survival, the doxorubicin arm was about 11 months and it wasn’t reached in the dostarlimab arm. Survival outcomes were clearly beneficial for the PD-L1 inhibitor in this population.


Mathews C, Lorusso D, Coleman RL, et al. The comparative clinical effectiveness of dostarlimab versus doxorubicin in the treatment of advanced/recurrent endometrial cancer. Presented at: 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Phoenix, Arizona.

Related Videos
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Pembrolizumab combined with carboplatin and paclitaxel resulted in response rates in patients with recurrent endometrial cancer.
Future analyses will look at durvalumab/olaparib for endometrial cancer populations with TP53 and POLE alterations, as well as those with estrogen receptor and progesterone receptor positivity.
Patients with mismatch repair proficient, newly diagnosed, advanced or recurrent endometrial cancer may have enhanced benefit with the addition of olaparib to durvalumab.
Dostarlimab plus chemotherapy produces notable benefits among patients with advanced, mismatch repair deficient endometrial cancer in the phase 3 RUBY trial.
Ritu Salani, MD, details the health-related quality of life benefits associated with dostarlimab in the treatment of advanced endometrial cancer, which includes improvements in back and pelvic pain.
Ritu Salani, MD, describes the concordance between blinded independent central review and provider-assessed outcomes with dostarlimab among patients with advanced recurrent endometrial cancer in the phase 3 RUBY trial.
Related Content